Literature DB >> 6848141

Augmentation by platelets of granulocyte aggregation in response to chemotaxins: studies utilizing an improved cell preparation technique.

H Redl, D E Hammerschmidt, G Schlag.   

Abstract

Considerable evidence exists to suggest roles for both platelets and granulocytes (PMNs) in pulmonary injury in shock. While believing that the major contributions of the two cell types are sequential, in vitro observations suggested that direct interactions between granulocytes and platelets might also amplify tissue damage. Using isotonic Percoll density gradients to isolate PMNs, we therefore studied the effect of deliberate platelet contamination on PMN aggregation. PMN aggregation in response to N-formyl-met-leu-phe or activated complement was enhanced by the presence of 1 platelet/PMN, an effect that became maximal at 16 platelets/PMN (p less than 0.01); large mixed aggregates were formed. Lysed, aspirinated, and indomethacin-treated platelets retained their augmentative capacity, as did platelets washed by gel filtration. The effect was not mimicked by the addition of histamine or serotonin to PMN preparations. None of these platelet preparations augmented lysosomal enzyme release. We conclude that platelets augment PMN aggregation, both by forming giant mixed PMN/platelet aggregates and also by producing a labile augmentative substance, the production of which may be independent of thromboxane synthesis. We propose that direct as well as sequential platelet/PMN interactions may be important in tissue injury in shock.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848141

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Inhibition of granulocyte function by steroids is not limited to corticoids. Studies with sex steroids.

Authors:  D E Hammerschmidt; A C Knabe; P T Silberstein; H R Lamche; P A Coppo
Journal:  Inflammation       Date:  1988-06       Impact factor: 4.092

2.  Rapid changes in light scattering from human polymorphonuclear leukocytes exposed to chemoattractants. Discrete responses correlated with chemotactic and secretory functions.

Authors:  I Yuli; R Snyderman
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

3.  Thiourea and dimethylthiourea decrease human neutrophil bactericidal function in vitro.

Authors:  J H Jackson; E M Berger; J E Repine
Journal:  Inflammation       Date:  1988-10       Impact factor: 4.092

4.  Cyanate-mediated inhibition of neutrophil myeloperoxidase activity.

Authors:  M Qian; J W Eaton; S P Wolff
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

5.  Inhibition by halothane, but not by isoflurane, of oxidative response to opsonized zymosan in whole blood.

Authors:  C Lieners; H Redl; G Schlag; D E Hammerschmidt
Journal:  Inflammation       Date:  1989-12       Impact factor: 4.092

6.  Aggregation, chemotaxis, and chemiluminescence of canine granulocytes. Studies utilizing improved cell preparation techniques.

Authors:  H Redl; P J Flynn; H Lamche; A Schiesser; G Schlag; D E Hammerschmidt
Journal:  Inflammation       Date:  1983-03       Impact factor: 4.092

Review 7.  [Current findings in the pathogenesis of the shock process in traumatology].

Authors:  G Schlag; H Redl
Journal:  Unfallchirurgie       Date:  1988-02

8.  Increased microvascular permeability in vivo in response to intradermal injection of neutrophil-activating protein (NAP-2) in rabbit skin.

Authors:  N Van Osselaer; J Van Damme; M Rampart; A G Herman
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

9.  Platelets mediate neutrophil-dependent immune complex nephritis in the rat.

Authors:  R J Johnson; C E Alpers; P Pritzl; M Schulze; P Baker; C Pruchno; W G Couser
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

10.  Cigarette smoking increases white blood cell aggregation in whole blood.

Authors:  A B Bridges; A Hill; J J Belch
Journal:  J R Soc Med       Date:  1993-03       Impact factor: 18.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.